An award-winning journalist, Derrick has written extensively about user fee negotiations, the FDA budget, FDA travel restrictions and drug advertising compliance. He also was part of the Pink Sheet team covering FDA's first biosimilar advisory committee meetings.
When he's not following FDA, Derrick is keeping close tabs on Indiana Hoosiers basketball.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Derrick Gingery
Senate committee votes to send the FDA Commissioner nominee to the Senate floor, but with only two Democratic votes.
When asked about Cures-related hiring, the FDA drug-center director says to her knowledge, no funding has been received yet.
FDA Commissioner nominee's answers to questions about his confidential committee paperwork did not arrive until minutes before the committee hearing, but Republicans' scheduling conflicts also may be to blame for the delay.
When asked about Cures-related hiring, CDER Director says to her knowledge, no funding has been received yet.
Update to 2005 outline of US response to pandemic influenza was due at the end of 2016, but has yet to be released.
Friends of Cancer Research seeks way of allowing high-quality efficacy data into label when supplemental NDA is not feasible.